Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.65 |
| ▸ | GSK3B | P49841 | 9/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652797 | 1.00 | PDE10A (0.65) | PDE10AGSK3BCYP1A2CYP2D6PDGFRB | |
| SCHEMBL14367677 | 0.91 | PDE10A (0.54) | PDE10AGSK3BCYP2D6PDGFRB | |
| SCHEMBL5651018 | 0.91 | PDE10A (0.54) | PDE10AGSK3BCYP2D6PDGFRB | |
| SCHEMBL4971994 | 0.90 | PDE10A (0.61) | PDE10AGSK3BCYP1A2CYP2D6PDGFRB | |
| SCHEMBL4972750 | 0.90 | PDE10A (0.61) | PDE10AGSK3BCYP1A2CYP2D6PDGFRB | |
| SCHEMBL4973098 | 0.90 | PDE10A (0.61) | PDE10AGSK3BCYP1A2CYP2D6PDGFRB | |
| SCHEMBL4173257 | 0.87 | PDE10A (0.50) | PDE10AGSK3BCYP1A2CYP2D6PDGFRB | |
| SCHEMBL14367680 | 0.84 | PDE10A (0.52) | PDE10AGSK3BPDGFRB | |
| SCHEMBL4987585 | 0.84 | PDE10A (0.52) | PDE10AGSK3BPDGFRB | |
| SCHEMBL4978026 | 0.84 | PDE10A (0.53) | PDE10AGSK3BCYP2D6PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | PDE10A 2/4885GSK3B 203/4885CYP1A2 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.